ATE355279T1 - Pyrazole als modulatoren des östrogenrezeptors - Google Patents
Pyrazole als modulatoren des östrogenrezeptorsInfo
- Publication number
- ATE355279T1 ATE355279T1 AT99940917T AT99940917T ATE355279T1 AT E355279 T1 ATE355279 T1 AT E355279T1 AT 99940917 T AT99940917 T AT 99940917T AT 99940917 T AT99940917 T AT 99940917T AT E355279 T1 ATE355279 T1 AT E355279T1
- Authority
- AT
- Austria
- Prior art keywords
- estrogen receptor
- pyrazoles
- modulators
- compounds
- modulating
- Prior art date
Links
- 102000015694 estrogen receptors Human genes 0.000 title abstract 4
- 108010038795 estrogen receptors Proteins 0.000 title abstract 4
- 150000003217 pyrazoles Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9577298P | 1998-08-07 | 1998-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE355279T1 true ATE355279T1 (de) | 2006-03-15 |
Family
ID=22253525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99940917T ATE355279T1 (de) | 1998-08-07 | 1999-08-06 | Pyrazole als modulatoren des östrogenrezeptors |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6291505B1 (de) |
| EP (1) | EP1102753B1 (de) |
| JP (1) | JP2002522422A (de) |
| AT (1) | ATE355279T1 (de) |
| AU (1) | AU5467799A (de) |
| DE (1) | DE69935335T2 (de) |
| ES (1) | ES2281186T3 (de) |
| WO (1) | WO2000007996A2 (de) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9912907A (pt) * | 1998-08-11 | 2001-05-08 | Bayer Agrochem Kk | Pirazóis nematicidas |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| GB0016787D0 (en) | 2000-07-07 | 2000-08-30 | Pfizer Ltd | Compounds useful in therapy |
| US6878729B2 (en) * | 2001-05-04 | 2005-04-12 | The Procter & Gamble Company | Medicinal uses of dihydropyrazoles |
| US7737185B2 (en) * | 2001-07-09 | 2010-06-15 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
| AU2002318225B2 (en) * | 2001-07-09 | 2007-12-13 | Repros Therapeutics Inc. | Methods and materials for the treatment of testosterone deficiency in men |
| US20040010027A1 (en) * | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
| ATE374753T1 (de) * | 2001-12-21 | 2007-10-15 | Vernalis Cambridge Ltd | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
| EP1465862A1 (de) * | 2002-01-17 | 2004-10-13 | SmithKline Beecham Corporation | Cycloalkyl-ketoamiden derivate und ihre verwendung als cathepsin-k-inhibitoren |
| ES2323952T3 (es) | 2002-05-15 | 2009-07-28 | Janssen Pharmaceutica Nv | 3-aminopirazol triciclicos sustituidos en n como inhibidores receptores de pdfg. |
| EP1398029A1 (de) * | 2002-09-10 | 2004-03-17 | LION Bioscience AG | 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden |
| GB0228417D0 (en) * | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| EP1606019A1 (de) * | 2003-03-07 | 2005-12-21 | The University Court of The University of Aberdeen | Inverse agonisten und neutrale antagonisten des cannabinoid-rezeptors als arzneimittel zur behandlung von knochenkrankheiten |
| WO2004080972A1 (en) * | 2003-03-12 | 2004-09-23 | Vertex Pharmaceuticals Incorporated | Pirazole modulators of atp-binding cassette transporters |
| US7205329B2 (en) * | 2003-05-30 | 2007-04-17 | Microbia, Inc. | Modulators of CRTH2 activity |
| US20070161698A1 (en) * | 2003-05-30 | 2007-07-12 | Microbia, Inc. | Modulators of CRTH2 Activity |
| US7465739B2 (en) | 2003-06-10 | 2008-12-16 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| JP2007527397A (ja) * | 2003-07-01 | 2007-09-27 | マイクロバイア インコーポレイテッド | Ｃｏｘ−２及びｆａａｈ阻害剤 |
| US20070293542A1 (en) * | 2003-10-16 | 2007-12-20 | Cali Brian M | Selective Cox-2 Inhibitors |
| US8088758B2 (en) | 2003-11-12 | 2012-01-03 | Abbott Products Gmbh | 17β-hydroxysteroid dehydrogenase type I inhibitors |
| MXPA06007326A (es) | 2003-12-23 | 2007-01-26 | Astex Therapeutics Ltd | Derivados de pirazol como moduladores de proteina cinasa. |
| US20050234244A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Synthesis of COX-2 and FAAH inhibitors |
| US20050234030A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
| US20080242726A1 (en) * | 2004-07-14 | 2008-10-02 | Podolski Joseph S | Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol |
| EP1797072A4 (de) * | 2004-09-17 | 2009-09-09 | Exelixis Inc | Pyrazolkinasemodulatoren und verwendungsverfahren |
| WO2006042172A2 (en) * | 2004-10-09 | 2006-04-20 | The Regents Of The University Of Michigan | Gender differences in experimental aortic aneurysm formation |
| PE20060949A1 (es) * | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| NZ556499A (en) * | 2005-02-04 | 2011-02-25 | Repros Therapeutics Inc | Methods and materials with trans-clomiphene for the treatment of male infertility |
| BRPI0609389A2 (pt) * | 2005-03-22 | 2010-03-30 | Repros Therapeutics Inc | tablete, composição e respectivos usos |
| TW200720254A (en) * | 2005-04-07 | 2007-06-01 | Nippon Kayaku Kk | Use of 3,5-diphenyl pyrazole derivatives as anti-tumor agent |
| WO2006116401A1 (en) * | 2005-04-28 | 2006-11-02 | Bristol-Myers Squibb Company | C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators |
| US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2006136837A2 (en) * | 2005-06-23 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
| AU2007275301A1 (en) * | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1 |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US20080096950A1 (en) * | 2006-10-19 | 2008-04-24 | Karl Richard Gibson | Compounds Useful In Therapy |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| BRPI0818637A2 (pt) | 2007-10-16 | 2015-04-07 | Repros Therapeutics Inc | Métodos de tratamento de sintoma da síndrome metabólica, de glicose em jejum prejudicada, da síndrome metabólica e de redução de níveis de glicose em, jejum em sujeito com hipogonadismo hipogonadotrófico secundário ou idiopático |
| KR20100122513A (ko) * | 2008-07-17 | 2010-11-22 | 아사히 가세이 파마 가부시키가이샤 | 질소 함유 복소환 화합물 |
| WO2010059788A1 (en) | 2008-11-20 | 2010-05-27 | Genentech, Inc. | Pyrazolopyridine pi3k inhibitor compounds and methods of use |
| TW201124406A (en) * | 2009-10-07 | 2011-07-16 | Karobio Ab | Novel estrogen receptor ligands |
| CA2793859C (en) | 2010-04-28 | 2018-02-13 | Toray Industries, Inc. | Therapeutic agent and preventative agent for alzheimer's disease |
| GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
| US9475816B2 (en) | 2012-09-07 | 2016-10-25 | Takeda Pharmaceutical Company Limited | Substituted-1,4-dihydropyrazolo[4,3-b]indoles |
| HK1216502A1 (zh) | 2012-11-02 | 2016-11-18 | Repros Therapeutics Inc. | 用於癌症治療的反式-克羅米芬 |
| TW201512215A (zh) | 2013-06-25 | 2015-04-01 | Forendo Pharma Ltd | 治療活性雌三烯噻唑衍生物 |
| JP6456373B2 (ja) | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
| JP6556125B2 (ja) | 2013-06-25 | 2019-08-07 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての治療的に活性な１７−窒素置換エストラトリエンチアゾール誘導体 |
| CN104016921A (zh) * | 2014-03-24 | 2014-09-03 | 南开大学 | 具有抗肝癌活性的1-取代苯基-4-多取代苯基-5-甲硫基-1h吡唑类化合物 |
| CN107207561B (zh) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
| JP6545266B2 (ja) | 2014-12-23 | 2019-07-17 | フォレンド ファーマ リミテッド | １７β‐ＨＳＤ１抑制剤のプロドラッグ |
| WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| CN105523955B (zh) * | 2015-12-14 | 2018-08-17 | 北京嘉林药业股份有限公司 | 化合物及其在制备药物中的用途 |
| GB201706806D0 (en) * | 2017-04-28 | 2017-06-14 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US20210002265A1 (en) * | 2018-03-02 | 2021-01-07 | Université de Lausanne | Pyrazole derivatives as inhibitors of the wnt signalling pathway |
| WO2025096683A1 (en) * | 2023-10-30 | 2025-05-08 | University Of Health Sciences And Pharmacy In St. Louis | Err modulators |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4146721A (en) * | 1969-09-12 | 1979-03-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyrazol-4-acetic acid compounds |
| FR2104932A1 (en) | 1970-09-08 | 1972-04-28 | Ferlux | O-hydroxyphenyl pyrazoles - hypocholesterolemics anti inflammatories analgesics etc |
| ZA744908B (en) | 1973-09-17 | 1975-08-27 | American Cyanamid Co | Catalytic dehydrogenation process for the preparation of 3,5-disubstituted pyrazoles |
| US4112108A (en) | 1976-12-06 | 1978-09-05 | Sandoz, Inc. | Isoxazolyl benzamides |
| US4229204A (en) | 1978-12-04 | 1980-10-21 | Monsanto Company | Trifluoromethylphenyl isoxazolyl benzoates |
| CA1128526A (en) | 1979-10-05 | 1982-07-27 | Cdc Life Sciences Inc. | 3,4-diarylisoxazol-5-acetic acids |
| DE3119727A1 (de) | 1981-05-18 | 1982-12-02 | Sterling Drug Inc., 10019 New York, N.Y. | "4-(arylaliphatische)-isoxazole, welche als antivirale mittel nuetzlich sind, und deren herstellung" |
| EP0442448A3 (en) * | 1990-02-13 | 1992-08-12 | Bristol-Myers Squibb Company | Heterocyclic carboxylic acids and esters |
| DE4126543A1 (de) * | 1991-08-10 | 1993-02-11 | Chem & Pharm Patent Hold Ltd | 3(5)-(hydroxyaryl)-pyrazole und ihre verwendung als wirkstoffe in arzneimittel |
| DE4230839A1 (de) | 1991-09-18 | 1993-03-25 | Ciba Geigy Ag | Polyarylenether mit pyrazoleinheiten |
| JPH06135948A (ja) | 1992-10-30 | 1994-05-17 | Taiho Yakuhin Kogyo Kk | スチレン誘導体又はその塩 |
| DE4408084A1 (de) | 1994-03-10 | 1995-09-14 | Hoechst Ag | 3,5-Disubstituierte und 3,4,5-trisubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| BR9607035A (pt) | 1995-02-13 | 1997-11-04 | Searle & Co | Isoxazois substituidos para o tratamento de inflamação |
| JPH11508267A (ja) | 1995-06-26 | 1999-07-21 | 藤沢薬品工業株式会社 | ピラゾール化合物および医薬組成物 |
| AU5041400A (en) | 1999-05-24 | 2000-12-12 | America River Nutrition, Inc. | Tocotrienols and geranylgeraniol from LTiGTbixa orellanaLT/iGT byproducts |
| DE60020560T2 (de) | 1999-06-03 | 2006-04-27 | Teikoku Hormone Mfg. Co., Ltd. | Substituierte pyrazol-derivate |
-
1999
- 1999-08-06 WO PCT/US1999/017799 patent/WO2000007996A2/en not_active Ceased
- 1999-08-06 EP EP99940917A patent/EP1102753B1/de not_active Expired - Lifetime
- 1999-08-06 ES ES99940917T patent/ES2281186T3/es not_active Expired - Lifetime
- 1999-08-06 US US09/369,747 patent/US6291505B1/en not_active Ceased
- 1999-08-06 JP JP2000563630A patent/JP2002522422A/ja not_active Ceased
- 1999-08-06 AT AT99940917T patent/ATE355279T1/de not_active IP Right Cessation
- 1999-08-06 DE DE69935335T patent/DE69935335T2/de not_active Expired - Lifetime
- 1999-08-06 AU AU54677/99A patent/AU5467799A/en not_active Abandoned
-
2001
- 2001-09-18 US US09/954,039 patent/US6727273B2/en not_active Expired - Fee Related
-
2003
- 2003-06-12 US US10/461,914 patent/US20040077701A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040077701A1 (en) | 2004-04-22 |
| JP2002522422A (ja) | 2002-07-23 |
| DE69935335T2 (de) | 2007-11-22 |
| WO2000007996A3 (en) | 2000-08-31 |
| EP1102753B1 (de) | 2007-02-28 |
| ES2281186T3 (es) | 2007-09-16 |
| US20040034081A9 (en) | 2004-02-19 |
| US6727273B2 (en) | 2004-04-27 |
| WO2000007996A2 (en) | 2000-02-17 |
| US6291505B1 (en) | 2001-09-18 |
| US20020111374A1 (en) | 2002-08-15 |
| DE69935335D1 (de) | 2007-04-12 |
| WO2000007996A8 (en) | 2000-10-19 |
| AU5467799A (en) | 2000-02-28 |
| EP1102753A2 (de) | 2001-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE355279T1 (de) | Pyrazole als modulatoren des östrogenrezeptors | |
| ATE315033T1 (de) | Subtituierte isoxazole derivate als estrogen rezeptor modulatore | |
| YU596A (sh) | Estrogen agonisti/antagonisti | |
| YU18400A (sh) | Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja | |
| AP9801269A0 (en) | Prostaglandin agonists. | |
| DE69914726D1 (de) | Zusammensetzung zur regulierung des hauterscheinungsbildes | |
| AU6045398A (en) | Androgen synthesis inhibitors | |
| MX9702865A (es) | Agentes estrogenicos. | |
| MX338710B (es) | Compuestos biciclicos moduladores de receptor de androgeno y progesterona, y metodos. | |
| SI1054887T1 (sl) | Biciklicni pridinski in primidinski derivati kot receptorski antagonisti nevropeptida y | |
| YU7797A (sh) | Kombinovana terapija za osteoporozu | |
| BG104247A (bg) | Производни на резорцинола | |
| MY121047A (en) | Bicyclo [2.2.1] heptanes and related compounds | |
| BR9710255A (pt) | Método para o tratamento de cáncer composto de retinóide de adamantila composição farmacéutica ou cosmética de matéria método de tratamento ou de prevenção e método para controlar | |
| AU9102198A (en) | Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens | |
| WO2001071022A3 (en) | Lpa receptor agonists and antagonists and methods of use | |
| AP1424A (en) | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens. | |
| MX9804588A (es) | Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel. | |
| EP0786995A4 (de) | ||
| MXPA04005784A (es) | 2-fenilbenzofuranos sustituidos como agentes estrogenitos. | |
| AU7096201A (en) | Phospholipid derivatives of valproic acid and mixtures thereof | |
| MY133390A (en) | Azabicyclic 5ht1 receptor ligands | |
| IL133483A0 (en) | Novel dihydronaphthalene compounds and processes of producing the same | |
| EP1339683A4 (de) | Östrogenrezeptormodulatoren | |
| GB9712966D0 (en) | Novel chalcones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1102753 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |